Globally, the blow fill seal equipment market is expected to rise with a CAGR of 6.2% during the forecast period, from US$ 337.3 Mn in 2020. The growth of this market is driven by the increasing demand for blow fill seal technology across pharmaceutical companies across the globe. Pharmaceutical companies are leveraging this technology for the packaging and storage of medicines. The high aseptic packaging nature of the technology along with the high speed of the operation makes it a suitable option for the pharmaceutical packaging.
Globally, the stretch blow molding machines market is expected to grow with a CAGR of 2.8% during the forecast period from 2021 to 2029, starting from US$755.6 Mn in 2020. The stretch blow molding machines are used for the production of containers and plastic bottles. At present, these machines are specially used in the manufacturing of soda bottles. These machines enable reliable manufacturing processes including bottle design, bottle molds, air preparation, and others.
Globally, the pressure reducing valve market is expected to grow with a CAGR of 4.2% through the forecast period, up from US$1.75 Bn in 2020. The growth of the market is attributed to the increasing adoption of the pressure reducing valves across the wide range of application across several industry verticals. The valves are widely used to maintain and relieve the pressure of the gas and fluids. The valve reduces the frequency of the unstable pressure and maintains a constant pressure via spring mechanism.
The capacitors for medical electronics market worldwide is estimated to grow with a CAGR of 6.9% through the forecast period starting from 2021 to 2029. Medical electronics market worldwide is observing continued growth over the past few years with more than 3.8% growth rate every year.
Globally, the direct-to-shape inkjet printing market is expected to grow with a CAGR of 6.3% during the forecast period from 2025 to 2033. At present, direct-to-shape inkjet printing is changing the packaging industry. This technology enables the printing of images and the texts directly on objects such as bottles, cans and other products. Along with the package decoration, it also helps to provide valuable information about the products.
The global spinal muscular atrophy treatment market is growing proficiently, expected to grow at a CAGR of 14.5%. Globally, the increasing incidence of SMA along with improved treatment management by innovative gene therapy and drugs will drive the growth of the market. Increasing awareness, FDA approval for new drugs, partnerships for enhanced R&D and private funding will boost the overall demand of SMA treatment on a global scale.
The hypoactive sexual desire disorder treatment market is set to expand at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Hypoactive sexual desire disorder (HSDD) can be primary, secondary, lifelong or situational; currently physicians worldwide are employing either psychotherapy or pharmacotherapy for its treatment. Recent approval of Bremelanotide (Vyleesi) will propel the HSDD market growth in the near future. Currently 2 drugs such as Prasterone 6.5 mg vaginal insert and BP101 are under phase 3 clinical trial being investigated for its safety and efficacy for treating HSDD.
Neutropenia treatment accounted for a market value of US$ 12,971.08 Mn in 2021 and projected to grow at a CAGR of 5.0% during the forecast period from 2025 to 2033. In neutropenia count of neutrophil falls giving rise to compromised immunity further increasing the risk of infection. Neutropenia is observed in almost half cases of cancer patients being treated with chemotherapy but out of them most are suffering from leukaemia.
Globally, the cognitive assessment and training market is expected to grow with a CAGR of 32.0% during the forecast period from 2019 to 2027, up from US$ 3.42 Bn in 2018. This market growth is attributed to the increasing elderly population across the globe. The population aging more than 60 years is growing rapidly worldwide. In 2015, more than 600 Mn populations across the globe were aging more than 60 years and it is estimated to increase cross the 2 Bn mark by 2050. The sudden increase in the life expectancy rate and sudden decline in the infertility rate is driving the growth of the geriatric population.
Devic’s syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 217.7 Mn in 2021 and projected to grow at a CAGR of 12.0% during the forecast period from 2025 to 2033. Devic's disease or neuromyelitis optica is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord, but in a few cases affect the brain.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.